An exploratory comparative analysis of tyrosine kinase inhibitors or docetaxel in second-line treatment of EGFR wild-type non-small-cell lung cancer: a retrospective real-world practice review at a single tertiary care centre

Ítems similars

• Response to: Second-line treatment of non-small-cell lung cancer with wild-type EGFR status. What is the best approach?
  per: Kim Anh, Ma, et al.
  Publicat: (2016)
• The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China
  per: Xu, Jianlin, et al.
  Publicat: (2016)
• Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts
  per: Tang, Ning, et al.
  Publicat: (2016)
• Lung cancer care trajectory at a Canadian centre: an evaluation of how wait times affect clinical outcomes
  per: Kasymjanova, G., et al.
  Publicat: (2017)
• Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec
  per: Agulnik, J., et al.
  Publicat: (2020)